In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

medac GmbH

www.medac.de

Latest From medac GmbH

Bookmark
  • News

Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations

By Maureen Kenny

Seven new drug applications got the thumbs up this week from the EMA's drug evaluation committee, the CHMP.  Their EU approval should now be a formality. Two new Shionogi treatments are set for approval, as are two orphan products – one from Medac, the other from AOP Orphan Pharmaceuticals. Pfizer got the OK for one biosimilar but has withdrawn an application for another.

Europe Regulation
Bookmark
  • News

CHMP Delays Review of Portola's Ondexxya; Who Will Pass Muster?

By Maureen Kenny
With its final meeting of the year under way, the EMA's medicines evaluation committee, the CHMP, will bring seasonal cheer for some companies if it decides their products merit EU approval. New treatments from Shionogi and Medac are up for an opinion. A planned appearance by Portola before the panel to answers questions relating to its marketing application for Ondexxya/AndexXa has been cancelled and the review period for the marketing authorization application for the product extended.
Europe BioPharmaceutical
Bookmark
  • Analysis

Deals Shaping The Medical Industry, July 2017

By Beth Detuzzi, Deanna Kamienski, Maureen Riordan, Steven Muntner and Amanda Micklus

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical
Bookmark
  • Analysis

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

By Joseph Haas

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • medac GmbH
  • medac GMBH
  • Medac GMBH
  • Senior Management
  • W. Mohr, Pres.
    Heiner Will, Chief Marketing Officer
  • Contact Info
  • medac GmbH
    Phone: (49) 4103 8006 0
    Theaterstr. 6
    Wedel, 22880
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By